In addition, in the view to reduce the sorafenib-mediated side effects and to maintain the efficiency of drug treatment, our findings provided a rationale for the use of the Akt inhibitor perifosine as an adjuvant with sorafenib in clinical trials of advanced BC.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}